Skip to content

The Effect of Soursop Supplementation on Blood Pressure, Serum Uric Acid and Kidney Function in Prehypertensive Patients

The Effect of Soursop Supplementation on Blood Pressure, Serum Uric Acid and Kidney Function in Prehypertensive Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03531203
Enrollment
143
Registered
2018-05-21
Start date
2017-07-10
Completion date
2018-01-19
Last updated
2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure, Prehypertension, Uric Acid

Keywords

soursop, supplementation, prehypertension, uric acid, randomized controlled trial

Brief summary

This study was a randomized controlled trial study. The aim of this study was to determine the effect of soursop fruit supplementation on blood pressure (BP), serum uric acid (SUA), and kidney function. The definition of prehypertension and hypertension was accepted as delivered in The Seventh Report of the Joint National Committee (JNC 7) as the systolic BP was 120 - 139 mmHg and diastolic BP was 80 - 89 mmHg for prehypertension, while systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg for hypertension. Based on the study by Sja'bani (2014), the cut-off point of (SUA) was divided into 3 categories, which are normal (\< 5 mg/dL), high-normal (5 - \<7 mg/dL), and high (≥ 7 mg/dL). A number of 143 people with essential prehypertension and high normal uric acid level were assigned as subject in this study. Subjects were randomly assigned into two groups which are treatment and control group. For a 3 months period, the treatment group was given 2x100 g soursop fruit juice per day and the control group was left without treatment. Blood pressure was measured by medical team using Omron HEM-907 (digital automatic blood pressure monitoring) every 2 weeks (3 times readings for each) in each subject's home. Subjects were examined in sitting position. Evaluation of laboratory examination was taken at week 0, 7 and 13.

Interventions

DIETARY_SUPPLEMENTSoursop supplementation

The soursop supplementation was given to treatment group (with soursop group) 2 times a day for 100 g each for 3 months period.

OTHERPlacebo

Control group (without soursop group) was left without treatment during study period

Sponsors

Mlati Study Group, Faculty of Medicine, Gadjah Mada University
CollaboratorUNKNOWN
Gadjah Mada University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to 59 Years
Healthy volunteers
No

Inclusion criteria

1. pre-hypertensive patients in accordance with JNC 7 (Joint National Committee 7) criteria, 2. male or female resident in Mlati, Sleman with or without family history of hypertension, 3. age 30-59 years, 4. high normal uric acid levels (≥ 5 and \< 7 mg/dL) and 5. agreed to follow the study by giving their informed consent.

Exclusion criteria

1. have a history of diabetes, chronic renal failure, 2. using hormonal contraceptive, 3. in pregnancy, 4. taking uric acid-lowering drugs (allopurinol, probenecid), 5. positive urine reduction, positive proteinuria, creatinine \> 1.5 g/dL, Blood Glucose \> 126 g/dL.

Design outcomes

Primary

MeasureTime frameDescription
Change in baseline morning home blood pressure at week 7 and 13Week 0, 7 and 13Blood pressure was measured by medical team using Omron HEM-907 (digital automatic blood pressure monitoring) every 2 weeks (3 times readings for each) in each subject's home. Subjects were examined in sitting position.
Change in baseline serum uric acid at week 7 and 13Week 0, 7 and 13Blood sample was taken to measure serum uric acid level

Secondary

MeasureTime frameDescription
Change in baseline CKD-Epi at week 7 and 13Week 0, 7 and 13Measurement of glomerular filtration rate
Change in baseline uric acid excretion at week 7 and 13Week 0, 7 and 1324-h urine sample was taken to measure uric acid excretion

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026